View Older Stories View More Recent Stories
-
IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Scott+Scott Attorneys at Law LLP Continues to Remind Investors an Action Has Been Filed Against Iovance Biotherapeutics, Inc. (IOVA)
-
Scott+Scott Attorneys at Law LLP Reminds Investors of The Securities Action That Has Been Filed Against Iovance Biotherapeutics, Inc. (IOVA)
-
Iovance Biotherapeutics (IOVA) Faces Investor Lawsuit Over Growth Projections Following Stock Plunge - Hagens Berman
-
IOVA SECURITIES UPDATE: Iovance Biotherapeutics, Inc. Investors with Losses are Reminded of the Upcoming July 14 Securities Class Action Deadline
-
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
-
Scott+Scott Attorneys at Law LLP Reminds Investors That There is a Securities Class Action Against Iovance Biotherapeutics, Inc. (IOVA)
-
Scott+Scott Attorneys at Law LLP Reminds Investors of the Class Action Against Iovance Biotherapeutics, Inc. (IOVA)
-
IOVA SECURITIES: BFA Law Notifies Iovance Biotherapeutics, Inc. Investors to Contact the Firm about the Pending Securities Fraud Class Action by July 14
-
ROSEN, A LEADING LAW FIRM, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IOVA
-
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
-
IOVA FRAUD NOTICE: Iovance Biotherapeutics, Inc. Investors with Losses are Reminded to Contact BFA Law about the Pending Securities Fraud Class Action
-
Scott+Scott Attorneys at Law LLP Reminds Investors of the Ongoing Action Against Iovance Biotherapeutics, Inc. (IOVA)
-
IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IOVA
-
Iovance Biotherapeutics (IOVA) announces results of Amtagvi to be presented at ASCO 2025
-
Scott+Scott Attorneys at Law LLP Reminds Investors a Securities Action Has Been Filed Against Iovance Biotherapeutics, Inc. (IOVA)
-
IOVA COURT ALERT: Iovance Biotherapeutics, Inc. Investors are Notified to Contact BFA Law before July 14 Legal Deadline
-
Scott+Scott Attorneys at Law LLP Alerts Investors an Action Has Been Filed Against Iovance Biotherapeutics, Inc. (IOVA)
-
Scott+Scott Attorneys at Law LLP Alerts Investors of The Pending Class Action Against Iovance Biotherapeutics, Inc. (IOVA)
-
Iovance Biotherapeutics (IOVA) Faces Investor Lawsuit Over Growth Projections Following Stock Plunge - Hagens Berman
-
IOVA NOTICE: Iovance Biotherapeutics, Inc. Investors with Losses are Alerted of the Upcoming July 14 Deadline in Securities Fraud Class Action
-
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
-
ROSEN, A LEADING LAW FIRM, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IOVA
-
IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
UBS Downgrades Iovanace Biotherapeutics (IOVA) to Neutral
-
Truist Securities Downgrades Iovanace Biotherapeutics (IOVA) to Hold
-
Iovanace Biotherapeutics (IOVA) PT Lowered to $20 at H.C. Wainwright
-
Baird Downgrades Iovanace Biotherapeutics (IOVA) to Neutral
-
Iovance Biotherapeutics (IOVA) Misses Q1 EPS by 12c
-
Iovanace Biotherapeutics (IOVA) PT Lowered to $5 at Barclays
-
Stifel Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA)
-
Iovanace Biotherapeutics (IOVA) PT Lowered to $18 at Jefferies
-
Iovanace Biotherapeutics (IOVA) PT Lowered to $18 at Stifel
-
Iovanace Biotherapeutics (IOVA) PT Lowered to $6 at Piper Sandler
-
Iovance Biotherapeutics (IOVA) Tops Q4 EPS by 1c
-
Stifel Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA)
-
Iovance Biotherapeutics (IOVA) Appoints Dan Kirby as Chief Commercial Officer
-
Iovanace Biotherapeutics (IOVA) PT Lowered to $7.50 at Piper Sandler
-
JMP Securities Biotechnology Overview
-
Truist Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA) Following Positive Amtagvi Survey
-
Stifel Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA)
-
Goldman Sachs Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA)
-
7 top biotech picks for 2025 according to Wells Fargo
-
Biotech outlook for 2025: Stifel
-
Stifel Highlights Iovanace Biotherapeutics (IOVA) as 'Top Pick' in Biotech's 2025 Outlook Note
-
Iovance Biotherapeutics (IOVA) Promotes Raj Puri to Chief Regulatory Officer
-
Iovance Biotherapeutics (IOVA) Tops Q3 EPS by 2c
-
UBS Starts Iovanace Biotherapeutics (IOVA) at Buy
-
Baird Reiterates Outperform Rating on Iovanace Biotherapeutics (IOVA)

